

# OPTIMA FAMILY CARE MEDALLION 4.0

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

Directions: *The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-844-723-2094. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.*

**Drug Requested:** Soliris (eculizumab) IV (J1300) (Medical)

**DRUG INFORMATION:** Complete all information below or authorization process will be delayed.

Drug Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code: \_\_\_\_\_

### **RECOMMENDED DOSAGE:**

- **Paroxysmal nocturnal hemoglobinuria (PNH):** IV: Induction: 600mg weekly for 4 doses; Maintenance: 900mg at week 5 then 900 mg every 2 weeks thereafter
- **Atypical hemolytic uremic syndrome (aHUS):** IV Induction: 900mg weekly x 4 doses; Maintenance 1200mg at week 5 then 1200mg q 2 weeks thereafter
- **Generalized myasthenia gravis (gMG):** IV Induction: 900mg weekly x 4 doses; Maintenance 1200mg at week 5 then 1200mg q 2 weeks thereafter

**CLINICAL CRITERIA:** Check **ALL** applicable boxes to qualify. **ALL** chart notes, including lab values, **MUST** be submitted with form or authorization process will be delayed.

**For INITIAL APPROVAL OF THERAPY, ALL of the following criteria MUST be met:**

- Patient does not have a systemic infection; **AND**
- Patients must be administered a meningococcal vaccine at least two weeks prior to initiation of Soliris therapy and revaccinated according to current medical guidelines for vaccine use; **OR**
- The member has not received a meningococcal vaccination at least two weeks prior to the initiation of therapy with Soliris and documented the risks of delaying Soliris therapy outweigh the risks of developing a meningococcal infection; **AND**
- The prescriber must be enrolled in the Soliris Risk Evaluation and Mitigation Strategy (REMS) program; **AND**
- The member must have **ONE** of the following conditions with the following criteria:

**For Diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH):**

- Member must have documented diagnosis of paroxysmal nocturnal hemoglobinuria confirmed by flow cytometry testing (*test results must be submitted*)  
**AND**
- The prescribing physician must be a hematologist or nephrologist

**For Diagnosis of Atypical Hemolytic Uremic Syndrome (aHUS):**

- Member must have diagnosis of atypical hemolytic uremic syndrome (aHUS) and documentation supporting a confirmed diagnosis (e.g. genetic testing, chart notes/lab results documenting evidence of microangiopathic hemolytic anemia, acute kidney injury and thrombocytopenia) must be submitted (*please attach*)  
**AND**
- The prescribing physician must be a hematologist or nephrologist

**For Diagnosis of Generalized Myasthenia Gravis (gMG):**

- Patient must be 18 years of age or older; **AND**
- The prescribing physician must be a neurologist; **AND**
- Patient must have Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to IV disease (*chart note documentation must be submitted*); **AND**
- Patient must have a positive serologic test for anti-acetylcholine receptor (AChR) antibodies (*lab results must be submitted*); **AND**
- Physician must have assessed the baseline Quantitative Myasthenia Gravis (QMG) score (*results must be submitted*); **AND**
- Patient has a MG-Activities of Daily Living (MG-ADL) total score of  $\geq 6$  (*results must be submitted*); **AND**

- Patient has failed treatment over at least 1 year with at least 2 immunosuppressive therapies (e.g. azathioprine, cyclosporine, mycophenolate, etc), **OR** has failed at least 1 immunosuppressive therapy and required chronic plasmapheresis or plasma exchange (PE) or intravenous immunoglobulin (IVIG) (*chart notes/pharmacy records must be submitted for documentation*)

**Length of Authorization:**

- For diagnosis of PNH and aHUS: Coverage will be provided for twelve months and may be renewed.
- For diagnosis of gMG: Initial coverage will be provided for 6 months and may be renewed annually thereafter

**RENEWAL CRITERIA: For continuation of therapy, ALL of the following MUST be met:**

**For Diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH):**

- Documentation of a positive clinical response, such as hemoglobin stabilization or a decrease in the number of red blood cell transfusions, must be submitted (*chart notes/labs must be submitted to document improvement*)

**For Diagnosis of Atypical Hemolytic Uremic Syndrome (aHUS):**

- An increase in mean platelet counts or hematologic normalization from baseline must be noted (*labs must be submitted to document improvement*)

**For Diagnosis of Generalized Myasthenia Gravis (gMG):**

- Subsequent 12 month authorizations will require documentation from a neurologist of a decrease in the MG-ADL total score from baseline (*results must be submitted to document improvement*); **AND**
- Improvement of at least 3-points from baseline in the Myasthenia Gravis-Specific Activities of Daily Living scale (MG-ADL) total score must be documented (*results must be submitted to document improvement*); **AND**
- Improvement of at least 5-points from baseline in the Quantitative Myasthenia Gravis (QMG) total score must be documented (*results must be submitted to document improvement*)

**EXCLUSIONS (Therapy will NOT be approved if member has history of any of the following:**

- History of thymoma or other neoplasms of the thymus
- History of thymectomy within 12 months prior to treatment
- MGFA Class I or MG crisis at initiation of treatment (MGFA Class V)
- Use of rituximab within 6 months prior to treatment
- Use of IVIG or PE within 4 weeks prior to treatment

**Medication being provided by: Please check applicable box(es) below.**

- Location/site of drug administration:** \_\_\_\_\_  
NPI or DEA # of administering location: \_\_\_\_\_

**OR**

- Specialty Pharmacy - PropriumRx**

**\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\***

**\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\***

Patient Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR /NPI #: \_\_\_\_\_

\*Approved by Pharmacy and Therapeutics Committee: 2/15/2018

REVISED/UPDATED: 7/1/2018